Q-omics provides the consensus-scored SEPTIN6 profile across patient tissues and cancer cell-line models. SEPTIN6 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, SEPTIN6 is differentially expressed in 13, with the highest sampling consensus in KIRP. Additionally, SEPTIN6 protein abundance shows 25,876 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight MESO, KIRP, and LSCC as cancer lineages where SEPTIN6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SEPTIN6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SEPTIN6 survival associations across molecular data types. SEPTIN6 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (5) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SEPTIN6 RNA expression–survival associations across cancer types. High SEPTIN6 expression shows unfavorable associations in MESO, UVM, LGG, UCS and ACC, but favorable associations in SKCM. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify MESO as the clearest survival context for SEPTIN6 RNA expression.
This table summarizes SEPTIN6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for SEPTIN6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SEPTIN6 shows lower tumor expression in KIRP, KIRC, COAD and BLCA and higher tumor expression in LIHC and BRCA. The KIRP box plot shows higher SEPTIN6 RNA expression in normal versus tumor tissue (log2 FC = −1.300, t-test p < 0.001).
This table shows molecular features associated with SEPTIN6 in patient tissues and cancer cell lines. In patient samples, SEPTIN6 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, SEPTIN6 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
